Isofol

Background / Insight
Isofol was founded in 2008 and focuses on the development and commercialization of arfolitixorin (drug candidate) – a new treatment that is expected to yield better results and fewer side effects for cancer patients.
As the existing graphic identity and brand platform did not align with Isofol's desired development and strategy, a complete overhaul was required. The goal of this work is to support Isofol's overall strategy for growth and commercialization.

Positioning / Strategy
Silver created a brand platform based on the position "Make Tomorrows Cancer Treatment better" with the brand drivers: "Real value," "Clinically validated," and "Commercial potential."

Visual Concept
The missing link: Isofol has found what’s missing in today’s cancer treatment, and that’s exactly where we found the inspiration for a new visual identity. We see the missing link in a larger context. It’s a symbol that we don’t replace, we complement. That we build upon what already exists and perfect it. Therefore, the visual expression is based on a simple but powerful idea: an almost complete structure where some puzzle pieces are missing.